NIH R01 · 2024
PROJECT SUMMARY/ABSTRACT In 2017, more than 550,000 people became sick with a strain of tuberculosis (TB) that was resistant to rifampin and isoniazid, the two most potent drugs in the standard first-line TB regimen. Historically, treatment for patients with multidrug-resistant (MDR) TB has been long, toxic, and ineffective: on average, only 55% of treated patients were cured at the end of the conventional 18- to 24-month regimen, which included a daily injection for approximately eight months. In 2012 and 2013 regulatory authorities conditionally approved the first new TB drugs in fifty years, bedaquiline (BDQ) and delamanid (DLM), offering hope for more effective and less toxic MDR-TB…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.